<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743622</url>
  </required_header>
  <id_info>
    <org_study_id>MIT 2019-02-020</org_study_id>
    <nct_id>NCT04743622</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost</brief_title>
  <official_title>Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and&#xD;
      BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel&#xD;
      Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not provided&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Actual">September 13, 2020</completion_date>
  <primary_completion_date type="Actual">June 23, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>(12-week-point)</time_frame>
    <description>The degree of staining of the cornea after blue fluorescein staining under the light of cobalt blue using a yellow filter was evaluated according to the Oxford grading system (0 to 5, the higher the worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival staining test</measure>
    <time_frame>(12-week-point)</time_frame>
    <description>The conjunctiva was divided into 6 areas and evaluated after the same staining method according to the Oxford grading system (0 to 3, the higher the worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular surface disease index (OSDI)</measure>
    <time_frame>(12-week-point)</time_frame>
    <description>The ocular surface was assessed using OSDI scoring questionnaire (0 to 100, the higher the worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance check</measure>
    <time_frame>(12-week-point)</time_frame>
    <description>Compliance of the drug administration has been check through the subject's self description (0 to 100, the higher the better)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>(4-week-point)</time_frame>
    <description>The degree of staining of the cornea after blue fluorescein staining under the light of cobalt blue using a yellow filter was evaluated according to the Oxford grading system(0 to 5, the higher the worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining test</measure>
    <time_frame>(4-week-point)</time_frame>
    <description>The conjunctiva was divided into 6 areas and evaluated after the same staining method according to the Oxford grading system (0 to 3, the higher the worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease indext (OSDI)</measure>
    <time_frame>(4-week-point)</time_frame>
    <description>The ocular surface was assessed using OSDI scoring questionnaire(0 to 100, the higher the worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP (intraocular pressure)</measure>
    <time_frame>(4- / 12-week-point)</time_frame>
    <description>IOP was measured using Goldmann applanation tonometry and measured in mmHg. (numerical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear break up time (TBUT)</measure>
    <time_frame>(4- / 12-week-point)</time_frame>
    <description>The time taken from the last blink to the appearance of a black spot on the cornea after fluorescein dye staining. (second, numerical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limbal and bulbar hyperemia</measure>
    <time_frame>(4- / 12-week-point)</time_frame>
    <description>The conjunctival hyperemia was assessed using Efron grading scales (0 to 4, the higher the worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Monoprost (preservative-free latanoprost eye drop)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>latanoprost : 1 drop once a day for 12 weeks to target eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xalatan (preserved latanoprost eye drop)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost : 1 drop once a day for 12 weeks to target eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monoprost</intervention_name>
    <description>preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes</description>
    <arm_group_label>Monoprost (preservative-free latanoprost eye drop)</arm_group_label>
    <other_name>Preservative-free latanoprost</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>preserved latanoprost 1 drop once a day for 12 weeks to target eyes</description>
    <arm_group_label>Xalatan (preserved latanoprost eye drop)</arm_group_label>
    <other_name>Preserved latanoprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IOP &gt;/= 15mmHg and &lt; 40 mmHg in each eye using Goldmann applanation tonometry at visit&#xD;
             2&#xD;
&#xD;
          -  Written consent voluntarily to participate in this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with closed-angle, congenital glaucoma or secondary glaucoma caused by&#xD;
             steroid drugs, etc.&#xD;
&#xD;
          -  best-corrected visual acuity 20/80 or less&#xD;
&#xD;
          -  Patients who have ongoing medical history of ocular inflammation&#xD;
&#xD;
          -  central corneal thickness is not in between 470um and 591um.&#xD;
&#xD;
          -  Patients who have received lacrimal duct procedure within the last 3 months or who&#xD;
             have plans to have it.&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seungsoo Rho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA Bundang Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA University Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <state>Bundang-gu</state>
        <zip>13497</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

